Developer docs
API playgroundTry for free, no card

Search company profiles

Pfizer

Full company profile

uuid003bcaq

Namestring
Pfizer
Legal namestring
ファイザー株式会社
Websiteurl
pfizer.co.jp
Company typeenum
Public
Founded yearint
1849
Descriptiontext

Pfizer Japan Inc. (ファイザー株式会社) is the Japanese operating subsidiary of Pfizer Inc., a Delaware-incorporated, NYSE-listed (PFE) global biopharmaceutical company headquartered in New York and founded in 1849. Pfizer Japan, headquartered in Shibuya-ku, Tokyo with a Pfizer Global Supply manufacturing facility in Nagoya, researches, develops, manufactures, and sells innovative prescription pharmaceuticals and vaccines. The company is organized around four end-to-end therapeutic areas: oncology, vaccines, internal medicine, and inflammation and immunology, with oncology further focused on breast, urologic, hematologic, and thoracic cancers.

The portfolio spans multiple drug modalities including small molecule compounds, mRNA vaccines (Comirnaty co-developed with BioNTech), antibody-drug conjugates (ADCs), bispecific antibodies (e.g., elranatamab), and gene therapy. Approved and pipeline products include Ibrance, Lorbrena, Abrysvo, Vepdegestrant/ARV-471, rimegepant/Nurtec, ritlecitinib, abrocitinib, Paxlovid, and vaccines for RSV, GBS, and C. difficile. Pfizer Japan also runs patient support platforms (the "がんと歩む" cancer patient app, ganclass.jp, enkei-datsumou.jp) and operates co-promotion partnerships with Bristol-Myers Squibb (Eliquis), Astellas (Abrysvo), and Tanabe Pharma (Govick).

Pfizer generates revenue primarily through prescription pharmaceutical and vaccine sales distributed via medical representatives (MRs) to hospitals, clinics, and pharmacies in Japan, with global manufacturing and supply through Pfizer Global Supply (PGS). Full-year 2024 consolidated revenue was $63.6 billion (up 6.7% YoY, 12% ex-COVID operational growth). Additional revenue streams include licensing deals (e.g., the $1.25 billion 3SBIO licensing arrangement). Pfizer also maintains licensing arrangements and co-development partnerships, and conducts over 50 clinical trials globally.

Short descriptiontext

Pfizer (ファイザー株式会社) is a global research-based pharmaceutical company that develops, manufactures, and sells prescription drugs and vaccines across oncology, vaccines, internal medicine, and inflammation/immunology, serving hospitals, clinics, healthcare providers, and patients worldwide via medical representatives and global supply chain.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersShibuya, Japan
HQ citystring
Shibuya
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, mRNA vaccine platform, oncology therapeutics, antibody drug conjugates, vaccine development
Industry4 codes
PRIMARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Drugs and Vaccines
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical product sales
TypeOne Time License
Description

Pfizer generates revenue primarily through the sale of prescription pharmaceuticals and vaccines. Full-year 2024 revenue was $63.6 billion, up 6.7% year-over-year. Operational growth excluding COVID products was 12%, driven by oncology, cardiovascular, and vaccine portfolios.

fortune.com
2Vaccines (Comirnaty)
TypeOne Time License
Description

COVID-19 vaccine Comirnaty and related vaccine products for various age groups, approved for Omicron variant JN.1 lineage LP.8.1

pfizer.co.jp
3Licensing deals
TypeLicensing Royalties
Description

$1.25 billion licensing deal with Chinese biopharma 3SBIO

mmm-online.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1がんと歩む
Description

Cancer patient support app for managing daily life, tracking health, and accessing cancer-related information

cancer.pfizer.co.jp
+5 more records
Core offering1 text field

Pfizer researches, develops, manufactures, and commercializes prescription pharmaceuticals and vaccines across four therapeutic areas: oncology, vaccines, internal medicine, and inflammation and immunology. Key products include Comirnaty (COVID-19 mRNA vaccine), Abrysvo (RSV vaccine), Ibrance (breast cancer), Lorbrena (lung cancer), Elranatamab (multiple myeloma), and Paxlovid (COVID-19 antiviral). The company serves healthcare providers, hospitals, clinics, and patients globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Full-year 2024 revenue of $63.6 billion, up 6.7% year-over-year
+1 more record
Product overview1 text field

Pfizer is a research-based pharmaceutical company with four end-to-end therapeutic areas: oncology, vaccines, internal medicine, and inflammation and immunology. The oncology portfolio focuses on four key areas (breast cancer, urological cancer, hematologic cancer, and thoracic/lung cancer) utilizing diverse drug technologies including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies. The vaccine portfolio includes Comirnaty (COVID-19 mRNA vaccine with BioNTech), Abrysvo (RSV vaccine), and pipeline candidates for RSV, GBS, and C. difficile. Internal medicine includes cardiovascular treatments, migraine treatments (rimegepant), and obesity treatments. The inflammation and immunology portfolio includes treatments for atopic dermatitis (abrocitinib, crisaborole), ulcerative colitis (tofacitinib, etrasimod), and alopecia areata (ritlecitinib). In 2024, Pfizer reported full-year revenue of $63.6 billion with operational growth excluding COVID products at 12%.

Product and service3 records
1Comirnaty (COVID-19 Vaccine)
CategoryVaccine
Description

mRNA-based COVID-19 vaccine developed in partnership with BioNTech, approved for multiple age groups including adults, children ages 5-11, and infants 6 months and older.

2Abrysvo (RSV Vaccine)
CategoryVaccine
Description

Respiratory syncytial virus (RSV) vaccine approved for adults, including expanded EU approval for adults aged 18-59 against RSV lower respiratory tract disease.

3Paxlovid (Nirmatrelvir/Ritonavir)
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-10
Description

Pfizer and BioNTech have obtained manufacturing and sales approval for COVID-19 vaccine Comirnaty for various age groups targeting the Omicron variant JN.1 lineage LP.8.1. The partnership combines BioNTech's mRNA technology with Pfizer's global manufacturing and distribution capabilities.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-03-11
Description

Pfizer and Arvinas announced positive topline results from Phase 3 VERITAC-2 clinical trial. Arvinas is developing PF-07850327 (ARV-471) for ER-positive/HER2-negative breast cancer, with Pfizer collaborating on clinical development.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-15
Description

PAHO, Argentina, Pfizer, and Sinergium are driving local production of 20-valent pneumococcal vaccine for Latin America and the Caribbean. This partnership aims to improve vaccine access and supply in the region.

4Bristol-Myers Squibb
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-promotion partnership for Eliquis (apixaban) in Japan. Both companies share information and coordinate on product promotion, clinical trials, and regulatory matters related to this anticoagulant medication.

pfizer.co.jp
5Tanabe Pharma
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Product: Govick injection for subcutaneous use. Partnership for co-promotion and information sharing in Japan.

pfizer.co.jp
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Product: Abrysvo. Partnership for co-promotion and information sharing in Japan for the RSV vaccine.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in vaccines (Shingrix, Arexvy vs. Pfizer's Abrysvo) and specialty pharmaceuticals; competes with Pfizer in respiratory, HIV, and oncology adjacencies.

TypeDirect peer
Description

Diversified global pharmaceutical company with overlapping oncology, cardiovascular, and immunology portfolios; comparable revenue scale and prescriber-channel business model.

TypeDirect peer
Description

Pure-play mRNA therapeutics and vaccines company; competes directly with Pfizer/BioNTech in COVID, RSV, and flu vaccines, and pursues similar oncology and rare disease mRNA programs.

TypeDirect peer
Description

Major pharma with strong oncology (Tagrisso, Imfinzi) and biologics platforms; competes with Pfizer in ADC development, vaccines, and cardiovascular/inflammation therapies.

TypeDirect peer
Description

Global research-based pharmaceutical company with similarly broad oncology and vaccine portfolios (Keytruda, Gardasil); competes head-to-head with Pfizer in oncology, vaccines, and hospital channel sales worldwide.

TypeDirect peer
Description

Major diversified pharma with overlapping oncology, immunology, and vaccine franchises; comparable global scale, R&D budget, and prescriber-focused commercial model.

7Bristol-Myers Squibb
TypeDirect peer
Description

Co-promotion partner on Eliquis and direct oncology competitor (Opdivo, Yervoy); comparable focus on oncology, hematology, and cardiovascular franchises with overlapping prescriber base.

TypeDirect peer
Description

Co-development partner on Comirnaty and independent mRNA competitor; directly comparable in mRNA technology platform, vaccine pipeline, and oncology immunotherapy programs.

TypeDirect peer
Description

Global vaccines and specialty care leader (Fluzone, Dupixent); competes with Pfizer across vaccines, immunology, and rare disease, with similar global commercial and manufacturing footprint.

TypeEmerging player
Description

Competitor in metabolic disease and oncology; Pfizer's exit from oral GLP-1 obesity (danuglipron) leaves Lilly dominant in the space, making it the leading obesity peer against which Pfizer's internal medicine pipeline is benchmarked.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pfizer

Pharmaceutical Drugs and Vaccinespfizer.co.jp

Pfizer (ファイザー株式会社) is a global research-based pharmaceutical company that develops, manufactures, and sells prescription drugs and vaccines across oncology, vaccines, internal medicine, and inflammation/immunology, serving hospitals, clinics, healthcare providers, and patients worldwide via medical representatives and global supply chain.

What Pfizer does

Pfizer Japan Inc. (ファイザー株式会社) is the Japanese operating subsidiary of Pfizer Inc., a Delaware-incorporated, NYSE-listed (PFE) global biopharmaceutical company headquartered in New York and founded in 1849. Pfizer Japan, headquartered in Shibuya-ku, Tokyo with a Pfizer Global Supply manufacturing facility in Nagoya, researches, develops, manufactures, and sells innovative prescription pharmaceuticals and vaccines. The company is organized around four end-to-end therapeutic areas: oncology, vaccines, internal medicine, and inflammation and immunology, with oncology further focused on breast, urologic, hematologic, and thoracic cancers.

The portfolio spans multiple drug modalities including small molecule compounds, mRNA vaccines (Comirnaty co-developed with BioNTech), antibody-drug conjugates (ADCs), bispecific antibodies (e.g., elranatamab), and gene therapy. Approved and pipeline products include Ibrance, Lorbrena, Abrysvo, Vepdegestrant/ARV-471, rimegepant/Nurtec, ritlecitinib, abrocitinib, Paxlovid, and vaccines for RSV, GBS, and C. difficile. Pfizer Japan also runs patient support platforms (the "がんと歩む" cancer patient app, ganclass.jp, enkei-datsumou.jp) and operates co-promotion partnerships with Bristol-Myers Squibb (Eliquis), Astellas (Abrysvo), and Tanabe Pharma (Govick).

Pfizer generates revenue primarily through prescription pharmaceutical and vaccine sales distributed via medical representatives (MRs) to hospitals, clinics, and pharmacies in Japan, with global manufacturing and supply through Pfizer Global Supply (PGS). Full-year 2024 consolidated revenue was $63.6 billion (up 6.7% YoY, 12% ex-COVID operational growth). Additional revenue streams include licensing deals (e.g., the $1.25 billion 3SBIO licensing arrangement). Pfizer also maintains licensing arrangements and co-development partnerships, and conducts over 50 clinical trials globally.

Pfizer firmographics

Firmographics
Name
Pfizer
Legal name
ファイザー株式会社
Website
https://pfizer.co.jp
Company type
Public
Founded year
1849
Operating status
Operating
Headcount range
101–250 employees
Short description
Pfizer (ファイザー株式会社) is a global research-based pharmaceutical company that develops, manufactures, and sells prescription drugs and vaccines across oncology, vaccines, internal medicine, and inflammation/immunology, serving hospitals, clinics, healthcare providers, and patients worldwide via medical representatives and global supply chain.
Ownership category
akta.pro rank

Pfizer industry classification

Industry
Product category
Pharmaceutical Drugs and Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Prescription pharmaceuticals
  • MRNA vaccine platform
  • Oncology therapeutics
  • Antibody drug conjugates
  • Vaccine development

Where Pfizer is headquartered

Location

Headquarters

HQ city
Shibuya
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

Pfizer business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical product sales: Pfizer generates revenue primarily through the sale of prescription pharmaceuticals and vaccines. Full-year 2024 revenue was $63.6 billion, up 6.7% year-over-year. Operational growth excluding COVID products was 12%, driven by oncology, cardiovascular, and vaccine portfolios.
  2. Vaccines (Comirnaty): COVID-19 vaccine Comirnaty and related vaccine products for various age groups, approved for Omicron variant JN.1 lineage LP.8.1
  3. Licensing deals: $1.25 billion licensing deal with Chinese biopharma 3SBIO

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Pfizer product offering

Product offering

Core offering

Pfizer researches, develops, manufactures, and commercializes prescription pharmaceuticals and vaccines across four therapeutic areas: oncology, vaccines, internal medicine, and inflammation and immunology. Key products include Comirnaty (COVID-19 mRNA vaccine), Abrysvo (RSV vaccine), Ibrance (breast cancer), Lorbrena (lung cancer), Elranatamab (multiple myeloma), and Paxlovid (COVID-19 antiviral). The company serves healthcare providers, hospitals, clinics, and patients globally.

Product overview

Pfizer is a research-based pharmaceutical company with four end-to-end therapeutic areas: oncology, vaccines, internal medicine, and inflammation and immunology. The oncology portfolio focuses on four key areas (breast cancer, urological cancer, hematologic cancer, and thoracic/lung cancer) utilizing diverse drug technologies including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies. The vaccine portfolio includes Comirnaty (COVID-19 mRNA vaccine with BioNTech), Abrysvo (RSV vaccine), and pipeline candidates for RSV, GBS, and C. difficile. Internal medicine includes cardiovascular treatments, migraine treatments (rimegepant), and obesity treatments. The inflammation and immunology portfolio includes treatments for atopic dermatitis (abrocitinib, crisaborole), ulcerative colitis (tofacitinib, etrasimod), and alopecia areata (ritlecitinib). In 2024, Pfizer reported full-year revenue of $63.6 billion with operational growth excluding COVID products at 12%.

Differentiator

Problem solved

Functional benefit

Brands

  • がんと歩む: Cancer patient support app for managing daily life, tracking health, and accessing cancer-related information
  • Comirnaty
  • ABRYSVO
  • パキロビッドパック
  • プレベナー20
  • タイコバック

Products and services

  • Comirnaty (COVID-19 Vaccine) mRNA-based COVID-19 vaccine developed in partnership with BioNTech, approved for multiple age groups including adults, children ages 5-11, and infants 6 months and older.
  • Abrysvo (RSV Vaccine) Respiratory syncytial virus (RSV) vaccine approved for adults, including expanded EU approval for adults aged 18-59 against RSV lower respiratory tract disease.
  • Paxlovid (Nirmatrelvir/Ritonavir)

Quantifiable outcome

  • Full-year 2024 revenue of $63.6 billion, up 6.7% year-over-year
  • +1 more outcomes

Companies that use Pfizer

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Pfizer technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Pfizer partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • BioNTechcoreStrategic or Co-development Partner · 10 August 2025Pfizer and BioNTech have obtained manufacturing and sales approval for COVID-19 vaccine Comirnaty for various age groups targeting the Omicron variant JN.1 lineage LP.8.1. The partnership combines BioNTech's mRNA technology with Pfizer's global manufacturing and distribution capabilities.
  • ArvinasminorStrategic or Co-development Partner · 11 March 2025Pfizer and Arvinas announced positive topline results from Phase 3 VERITAC-2 clinical trial. Arvinas is developing PF-07850327 (ARV-471) for ER-positive/HER2-negative breast cancer, with Pfizer collaborating on clinical development.
  • PAHO, Argentina, and SinergiumminorStrategic or Co-development Partner · 15 January 2025PAHO, Argentina, Pfizer, and Sinergium are driving local production of 20-valent pneumococcal vaccine for Latin America and the Caribbean. This partnership aims to improve vaccine access and supply in the region.
  • Bristol-Myers SquibbcoreStrategic or Co-development PartnerCo-promotion partnership for Eliquis (apixaban) in Japan. Both companies share information and coordinate on product promotion, clinical trials, and regulatory matters related to this anticoagulant medication.
  • Tanabe PharmaminorStrategic or Co-development PartnerProduct: Govick injection for subcutaneous use. Partnership for co-promotion and information sharing in Japan.
  • Astellas PharmaminorStrategic or Co-development PartnerProduct: Abrysvo. Partnership for co-promotion and information sharing in Japan for the RSV vaccine.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Pfizer competitors and assessment

Company assessment

Direct peers

  • GSK: Direct competitor in vaccines (Shingrix, Arexvy vs. Pfizer's Abrysvo) and specialty pharmaceuticals; competes with Pfizer in respiratory, HIV, and oncology adjacencies.
  • Novartis: Diversified global pharmaceutical company with overlapping oncology, cardiovascular, and immunology portfolios; comparable revenue scale and prescriber-channel business model.
  • Moderna: Pure-play mRNA therapeutics and vaccines company; competes directly with Pfizer/BioNTech in COVID, RSV, and flu vaccines, and pursues similar oncology and rare disease mRNA programs.
  • AstraZeneca: Major pharma with strong oncology (Tagrisso, Imfinzi) and biologics platforms; competes with Pfizer in ADC development, vaccines, and cardiovascular/inflammation therapies.
  • Merck & Co. (MSD): Global research-based pharmaceutical company with similarly broad oncology and vaccine portfolios (Keytruda, Gardasil); competes head-to-head with Pfizer in oncology, vaccines, and hospital channel sales worldwide.
  • Johnson & Johnson (Innovative Medicine): Major diversified pharma with overlapping oncology, immunology, and vaccine franchises; comparable global scale, R&D budget, and prescriber-focused commercial model.
  • Bristol-Myers Squibb: Co-promotion partner on Eliquis and direct oncology competitor (Opdivo, Yervoy); comparable focus on oncology, hematology, and cardiovascular franchises with overlapping prescriber base.
  • BioNTech: Co-development partner on Comirnaty and independent mRNA competitor; directly comparable in mRNA technology platform, vaccine pipeline, and oncology immunotherapy programs.
  • Sanofi: Global vaccines and specialty care leader (Fluzone, Dupixent); competes with Pfizer across vaccines, immunology, and rare disease, with similar global commercial and manufacturing footprint.

Emerging players

  • Eli Lilly: Competitor in metabolic disease and oncology; Pfizer's exit from oral GLP-1 obesity (danuglipron) leaves Lilly dominant in the space, making it the leading obesity peer against which Pfizer's internal medicine pipeline is benchmarked.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Pfizer social profiles

Digital presence

Pfizer financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pfizer leadership team

Management profile

Number of profiles

Profiles1 record

Pfizer subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Pfizer funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pfizer M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pfizer

What does Pfizer do?

Pfizer researches, develops, manufactures, and commercializes prescription pharmaceuticals and vaccines across four therapeutic areas: oncology, vaccines, internal medicine, and inflammation and immunology. Key products include Comirnaty (COVID-19 mRNA vaccine), Abrysvo (RSV vaccine), Ibrance (breast cancer), Lorbrena (lung cancer), Elranatamab (multiple myeloma), and Paxlovid (COVID-19 antiviral). The company serves healthcare providers, hospitals, clinics, and patients globally.

Is Pfizer a public or private company?

Pfizer is a public company. It is classified as public and is currently operating.

When was Pfizer founded?

Pfizer was founded in 1849. It employs 101 to 250 people.

Where is Pfizer based?

Pfizer is headquartered in Shibuya, Japan, in the Asia region.

How does Pfizer make money?

Three revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are vaccines (Comirnaty) and licensing deals.

Who are Pfizer's main competitors?

Direct peers on record are GSK, Novartis, Moderna, AstraZeneca, Merck & Co. (MSD), Johnson & Johnson (Innovative Medicine), Bristol-Myers Squibb, BioNTech and Sanofi. Eli Lilly is listed as an emerging player.

Does Pfizer have an API?

No public API is recorded for Pfizer.

What industry is Pfizer in?

Pfizer's product category is Pharmaceutical Drugs and Vaccines. Its primary akta.pro industry code is HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals